Long-term treatment of hereditary angioedema with attenuated androgens: A survey of a 13-year experience

Marco Cicardi, Luigi Bergamaschini, Massimo Cugno, Erik Hack, Giovanni Agostoni, Angelo Agostoni

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

Fifty-six patients affected with hereditary angioedema have been followed during long-term prophylaxis with attenuated androgens. The treatment was started in patients who had one or more severe attacks per month. In 24 patients, the therapy lasted for more than 5 years. The minimal effective dose usually did not exceed 2 mg/day of stanozolol or 200 mg/day of danazol. Only in two patients were these doses not sufficient to achieve the complete disappearance of symptoms. Irregular menstruation, but rarely amenorrhea, was the only significant side effect. One patient had to stop the therapy because of laboratory signs of hepatic cell necrosis. In one patient, danazol was administered during the last 8 weeks of pregnancy without side effects for the mother but with transient signs of virilization for the female baby. To find a biochemical marker for the minimal effective dose of androgen derivatives, we measured the plasma levels of C1 C1 INH complexes at different doses of stanozolol in four patients with hereditary angioedema. We found that these complexes, elevated before treatment, promptly reverted to normal values during androgen therapy and remained normal with any reduction of the dose of the drug as long as the patient remained symptom free. Therefore, the measurement of C1 C1 INH complexes appears to reflect the activity of the disease and not the amount of androgen that is administered. (J Allergy Clin Immunol 1991;87:768-73.).

Original languageEnglish
Pages (from-to)768-773
Number of pages6
JournalJournal of Allergy and Clinical Immunology
Volume87
Issue number4
DOIs
Publication statusPublished - 1991

Fingerprint

Hereditary Angioedemas
Androgens
Stanozolol
Danazol
Therapeutics
Virilism
Menstruation
Surveys and Questionnaires
Amenorrhea
Hepatocytes
Hypersensitivity
Reference Values
Necrosis
Biomarkers
Mothers
Pregnancy

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Long-term treatment of hereditary angioedema with attenuated androgens : A survey of a 13-year experience. / Cicardi, Marco; Bergamaschini, Luigi; Cugno, Massimo; Hack, Erik; Agostoni, Giovanni; Agostoni, Angelo.

In: Journal of Allergy and Clinical Immunology, Vol. 87, No. 4, 1991, p. 768-773.

Research output: Contribution to journalArticle

Cicardi, Marco ; Bergamaschini, Luigi ; Cugno, Massimo ; Hack, Erik ; Agostoni, Giovanni ; Agostoni, Angelo. / Long-term treatment of hereditary angioedema with attenuated androgens : A survey of a 13-year experience. In: Journal of Allergy and Clinical Immunology. 1991 ; Vol. 87, No. 4. pp. 768-773.
@article{03ecd11564c94dd182c9a46e3490a6a8,
title = "Long-term treatment of hereditary angioedema with attenuated androgens: A survey of a 13-year experience",
abstract = "Fifty-six patients affected with hereditary angioedema have been followed during long-term prophylaxis with attenuated androgens. The treatment was started in patients who had one or more severe attacks per month. In 24 patients, the therapy lasted for more than 5 years. The minimal effective dose usually did not exceed 2 mg/day of stanozolol or 200 mg/day of danazol. Only in two patients were these doses not sufficient to achieve the complete disappearance of symptoms. Irregular menstruation, but rarely amenorrhea, was the only significant side effect. One patient had to stop the therapy because of laboratory signs of hepatic cell necrosis. In one patient, danazol was administered during the last 8 weeks of pregnancy without side effects for the mother but with transient signs of virilization for the female baby. To find a biochemical marker for the minimal effective dose of androgen derivatives, we measured the plasma levels of C1 C1 INH complexes at different doses of stanozolol in four patients with hereditary angioedema. We found that these complexes, elevated before treatment, promptly reverted to normal values during androgen therapy and remained normal with any reduction of the dose of the drug as long as the patient remained symptom free. Therefore, the measurement of C1 C1 INH complexes appears to reflect the activity of the disease and not the amount of androgen that is administered. (J Allergy Clin Immunol 1991;87:768-73.).",
author = "Marco Cicardi and Luigi Bergamaschini and Massimo Cugno and Erik Hack and Giovanni Agostoni and Angelo Agostoni",
year = "1991",
doi = "10.1016/0091-6749(91)90120-D",
language = "English",
volume = "87",
pages = "768--773",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Long-term treatment of hereditary angioedema with attenuated androgens

T2 - A survey of a 13-year experience

AU - Cicardi, Marco

AU - Bergamaschini, Luigi

AU - Cugno, Massimo

AU - Hack, Erik

AU - Agostoni, Giovanni

AU - Agostoni, Angelo

PY - 1991

Y1 - 1991

N2 - Fifty-six patients affected with hereditary angioedema have been followed during long-term prophylaxis with attenuated androgens. The treatment was started in patients who had one or more severe attacks per month. In 24 patients, the therapy lasted for more than 5 years. The minimal effective dose usually did not exceed 2 mg/day of stanozolol or 200 mg/day of danazol. Only in two patients were these doses not sufficient to achieve the complete disappearance of symptoms. Irregular menstruation, but rarely amenorrhea, was the only significant side effect. One patient had to stop the therapy because of laboratory signs of hepatic cell necrosis. In one patient, danazol was administered during the last 8 weeks of pregnancy without side effects for the mother but with transient signs of virilization for the female baby. To find a biochemical marker for the minimal effective dose of androgen derivatives, we measured the plasma levels of C1 C1 INH complexes at different doses of stanozolol in four patients with hereditary angioedema. We found that these complexes, elevated before treatment, promptly reverted to normal values during androgen therapy and remained normal with any reduction of the dose of the drug as long as the patient remained symptom free. Therefore, the measurement of C1 C1 INH complexes appears to reflect the activity of the disease and not the amount of androgen that is administered. (J Allergy Clin Immunol 1991;87:768-73.).

AB - Fifty-six patients affected with hereditary angioedema have been followed during long-term prophylaxis with attenuated androgens. The treatment was started in patients who had one or more severe attacks per month. In 24 patients, the therapy lasted for more than 5 years. The minimal effective dose usually did not exceed 2 mg/day of stanozolol or 200 mg/day of danazol. Only in two patients were these doses not sufficient to achieve the complete disappearance of symptoms. Irregular menstruation, but rarely amenorrhea, was the only significant side effect. One patient had to stop the therapy because of laboratory signs of hepatic cell necrosis. In one patient, danazol was administered during the last 8 weeks of pregnancy without side effects for the mother but with transient signs of virilization for the female baby. To find a biochemical marker for the minimal effective dose of androgen derivatives, we measured the plasma levels of C1 C1 INH complexes at different doses of stanozolol in four patients with hereditary angioedema. We found that these complexes, elevated before treatment, promptly reverted to normal values during androgen therapy and remained normal with any reduction of the dose of the drug as long as the patient remained symptom free. Therefore, the measurement of C1 C1 INH complexes appears to reflect the activity of the disease and not the amount of androgen that is administered. (J Allergy Clin Immunol 1991;87:768-73.).

UR - http://www.scopus.com/inward/record.url?scp=0025874826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025874826&partnerID=8YFLogxK

U2 - 10.1016/0091-6749(91)90120-D

DO - 10.1016/0091-6749(91)90120-D

M3 - Article

C2 - 2013670

AN - SCOPUS:0025874826

VL - 87

SP - 768

EP - 773

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 4

ER -